Áß¾Ó´ëÇб³±¤¸íº´¿ø Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸ P-TRG(Platelet-Thrombosis Research Group) 2022 : 2022-10-15±³À°ÀÏÀÚ : 2022-10-15
±³À°Àå¼Ò : Áß¾Ó´ëÇб³±¤¸íº´¿ø, ±èºÎ¼·È¦(5F)
±³À°ÁÖÁ¦ :
P-TRG(Platelet-Thrombosis Research Group) 2022ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸
´ã´çÀÚ : Á¶¿¹¸®
¿¬¶ôó : 02-582-8222
À̸ÞÀÏ :
yehc@kscvi.org ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 120¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
°æ±âµµ±³À°½Ã°£ : 7 ½Ã°£ 15ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í -Á¤È¸¿ø ¹«·á µî·Ï -Àü¹®ÀÇ/°³¿øÀÇ/ÀϹÝÀÇ: 60,000 -ÀüÀÓÀÇ/Àü°øÀÇ: 30,000 -°£È£»ç/ÀÇ·á±â»ç/ÀÇ´ë»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/ÀÓ»óº´¸®»ç/Àǹ«±â·Ï»ç: 20,000 -»ê¾÷ü/±âŸ: 120,000 * ÇöÀåµî·Ï¸¸ °¡´ÉÇÕ´Ï´Ù.
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 09:00~09:10 Genotype-Guided Oral P2Y12 Inhibitor Therapy Reduces Cumulative Ischemic Events Following Percutaneous Coronary Intervention - A Prespecified Secondary Analysis of the TAILOR-PCI(Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention) Randomised Trial Â÷Á¤ÁØ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 09:10~09:20 INVICTUS(Investigation of Rheumatic AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies) - Rivaroxaban versus VKA(Vitamin K antagonists) for Rheumatic Atrial Fibrillation Çã¾Ö¿µ(°¿øÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 09:20~09:30 PACIFIC-AMI(Acute Myocardial Infarction) - Efficacy and Safety of Factor XIa Inhibitor Asundexian on Top of Dual Antiplatelet Therapy after Acute Myocardial Infarction ¿øÈ£¿¬(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 09:30~09:40 Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR(Transcatheter Aortic Valve Replacement) - ADAPT-TAVR(Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement) °µµÀ±(¿ï»êÀÇ´ë)
Åä·Ð 10-15 ±èºÎ¼·È¦(5F) 09:40~10:00 Discussion ()
ÈÞ½Ä 10-15 10:00~10:10 Coffee Break ()
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 10:10~10:25 Atherothrombotic Events after COVD-19 Vaccination in Korea ³ª»óÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 10:25~10:40 Medical Management of COVID-19 Coagulopathy Á¶Á¤·¡(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 10:40~10:55 Laboratory Approach for the Platelet Function Disorders ¹Ú»óÇõ(¿ï»êÀÇ´ë)
Åä·Ð 10-15 ±èºÎ¼·È¦(5F) 10:55~11:10 Discussion ()
ÈÞ½Ä 10-15 11:10~11:20 Coffee Break ()
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 11:20~11:35 Treatment of AF(Atrial Fibrillation) in Korean Patients: Perspectives from the Big Data ¾çÇʼº(Â÷ÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 11:35~11:50 Anti-thrombotic Therapy in AF(Atrial Fibrillation) PCI(Percutaneous Coronary Intervention) Patients: Interventionist ÀÌÁ¾¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 11:50~12:05 Updates of Korean AF(Atrial Fibrillation) Guideline: What Is New? ÀÌÁ¤¸í(°æÈñÀÇ´ë)
Åä·Ð 10-15 ±èºÎ¼·È¦(5F) 12:05~12:20 Discussion ()
±âŸ 10-15 ±èºÎ¼·È¦(5F) 12:20~12:30 P-TRG ÃÑȸ ()
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 12:30~12:45 Cutting-Edge Care of Pitavastatin+Ezetimibe Combination Therapy ¹Ú¿ëÈÖ(°æ»óÀÇ´ë)
½Ä»ç 10-15 12:45~13:30 Lunch Break ()
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 13:30~13:40 Aspirin Monotherapy Is Enough after 1-year post-PCI(Percutaneous Coronary Intervention) ±Ç¿À¼º(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 13:40~13:50 DAPT(Dual Antiplatelet Therapy) Continuation Is Better in High-risk Patients after 1-year post-PCI(Percutaneous Coronary Intervention) ÀüÈ£¼º(¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 13:50~14:00 Clopidogrel Monotherapy Is Better in High-risk Patients after 1-year post-PCI(Percutaneous Coronary Intervention) À̽ÂÁØ(¿¬¼¼ÀÇ´ë)
Åä·Ð 10-15 ±èºÎ¼·È¦(5F) 14:00~14:15 Discussion ()
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 14:15~14:25 Recent Data Review: Antithrombotic Therapy 1-year after PCI(Percutaneous Coronary Intervention) in AF(Atrial Fibrillation) Patient À̽ÂÇå(Àü³²ÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 14:25~14:35 NOAC(New Oral Anticoagulant) Alone Is Enough ÁøÇÑ¿µ(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 14:35~14:45 NOAC(New Oral Anticoagulant) Alone Is Not Enough, Antiplatelet Agent with NOAC(New Oral Anticoagulant) Should Be Continued ÃÖ±âÈ«(¼º±Õ°üÀÇ´ë)
Åä·Ð 10-15 ±èºÎ¼·È¦(5F) 14:45~15:00 Discussion ()
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 15:00~15:15 Anticoagulant Strategy in Korean Patients À̱âÈ«(Àü³²ÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 15:15~15:30 Prognostic Implication of Polygenic Risk Score in Korean Population À̽ÂÇ¥(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 15:30~15:45 Charateristics of Dyslipidemia and Treatment Issues in Korean Population Á¤Ã¢Èñ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 15:45~16:00 Treatment Guide according to Thrombogenicity in Korean Patients Á¤¿µÈÆ(Áß¾ÓÀÇ´ë)
Åä·Ð 10-15 ±èºÎ¼·È¦(5F) 16:00~16:20 Discussion ()
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 16:20~16:30 Relapsed NSTEMI(Non-ST Segment Elevation Myocardial Infarction) due to Acute Gastrointestinal Bleeding after NSTEMI(Non-ST Segment Elevation Myocardial Infarction) ±èµµ¿ø(Á¤ÇÑ»ù³»°úÀÇ¿ø)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 16:30~16:40 Acute Myocardial Infarction Patient with Severe Thrombocytopenia ±èÇü¿À(»ïÀ°¼¿ïº´¿ø)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 16:40~16:50 Successful PCI(Percutaneous Coronary Intervention) in Hemophilia A Patient with Acute Myocardial Infarction Occurring at a Prior Documented Minimal Coronary Artery Lesion ¹Ú»ó¹Î(À»ÁöÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 16:50~17:00 Triple Antithrombotic Treatment and Staged Elective PCI(Percutaneous Coronary Intervention) for Q-wave Myocardial Infarction with Suspected of Multiple Thrombus Occlusion ¼¿µÈÆ(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 17:00~17:10 MI(Myocardial Infarction) ȯÀÚ¿¡¼ Staged Noninfarct-related Artery ½Ã¼ú Á÷ÈÄ ¹ß»ýÇÑ Infarct-related ArteryÀÇ Stent Thrombosis, ±×¸®°í ÀÌÀÇ Ä¡·á ÈÄ ¹ß»ýÇÑ Retroperitoneal Hemorrhage Áõ·Ê ÀÌÀ籤(â¿øÆÄƼ¸¶º´¿ø)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 17:10~17:20 Thrombosis, Thrombosis, and Thrombosis in a Patient with STEMI(ST-elevation Myocardial Infarction) undergoing Primary PCI(Percutaneous Coronary Intervention) ÀüÈ£¼º(¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 17:20~17:30 Hemorrhoids Bleeding, Is That a Simple Matter? õ´ë¿µ(ÇѸ²ÀÇ´ë)